Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models
Science Translational Medicine · 2024
DOI: 10.1126/scitranslmed.ado4463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2024. Verfasst von Alice Dejoux und 36 weiteren Autor:innen. Beteiligte Einrichtung: Institut Pasteur, Université Paris Cité, INSERM UMR1222, Antibodies in Therapy and Pathology, 75015 Paris, France. Hauptthemen laut MEDLINE: Rocuronium, Anaphylaxis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 94 Literaturangaben.
Abstract (Originalsprache)
Neuromuscular blocking agents (NMBAs) relax skeletal muscles to facilitate surgeries and ease intubation but can lead to adverse reactions, including complications because of postoperative residual neuromuscular blockade (rNMB) and, in rare cases, anaphylaxis. Both adverse reactions vary between types of NMBAs, with rocuronium, a widely used nondepolarizing NMBA, inducing one of the longest rNMB durations and highest anaphylaxis incidences. rNMB induced by rocuronium can be reversed by the synthetic γ-cyclodextrin sugammadex. However, in rare cases, sugammadex can provoke anaphylaxis. Thus, additional therapeutic options are needed. Rocuronium-induced anaphylaxis is proposed to rely on preexisting rocuronium-binding antibodies. To understand the pathogenesis of rocuronium-induced anaphylaxis and to identify potential therapeutics, we investigated the memory B cell antibody repertoire of patients with suspected hypersensitivity to rocuronium. We identified polyclonal antibody repertoires with a high diversity among V(D)J genes without evidence of clonal groups. When recombinantly expressed, these antibodies demonstrated specificity and low affinity for rocuronium without cross-reactivity for other NMBAs. Moreover, when these antibodies were expressed as human immunoglobulin E (IgE), they triggered human mast cell activation and passive systemic anaphylaxis in transgenic mice, although their affinities were insufficient to serve as reversal agents. Rocuronium-specific, high-affinity antibodies were thus isolated from rocuronium-immunized mice. The highest-affinity antibody was able to reverse rocuronium-induced neuromuscular blockade in nonhuman primates with kinetics comparable to that of sugammadex. Together, these data support the hypothesis that antibodies cause anaphylactic reactions to rocuronium and pave the way for improved diagnostics and neuromuscular blockade reversal agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institut Pasteur, Université Paris Cité, INSERM UMR1222, Antibodies in Therapy and Pathology, 75015 Paris, France.
- Sorbonne Université, Collège Doctoral, 75005 Paris, France.
- Université Paris-Saclay, INSERM, Inflammation Microbiome Immunosurveillance, 91400 Orsay, France.
- Institut Pasteur, Université Paris Cité, CNRS UMR3523, Chimie des Biomolécules, 75015 Paris, France.
- Université Paris-Saclay, INSERM, CEA, Center for Immunology of Viral, Autoimmune, Hematological and Bacterial Diseases, 92260 Fontenay-aux-Roses and 94250 Le Kremlin-Bicêtre, France.
- Institut Necker Enfants Malades, INSERM U1151/CNRS UMR 8253, Action thématique incitative sur programme-Avenir Team, Auto-Immune and Immune B cells, Université Paris Cité, Université Paris Est-Créteil, 94000 Créteil, Fr…
ORCID-Profile: Alice Dejoux, Qianqian Zhu, Odile Richard-Le Goff, Ophélie Godon, Julien Lemaitre, Francis Relouzat, François Huetz, Aurélien Sokal, Cyprien Pecalvel, Thomas Derenne, Caitlin M Gillis, Yidan Wang, Thierry Rose, Christel Mertens, Pascale Nicaise-Roland, Matthieu Mahévas, Luc de Chaisemartin, Roger Le Grand, Hélène Letscher, Ahmed Haouz, Laurent L Reber, Pascal Chappert, Friederike Jönsson, Didier G Ebo, Gaël A Millot, Sylvie Bay, Sylvie Chollet-Martin, Aurélie Gouel-Chéron, Pierre Bruhns
Zitieren
APA
Dejoux, A., Zhu, Q., Ganneau, C., Goff, O. R., Godon, O., Lemaitre, J., Relouzat, F., Huetz, F., Sokal, A., Vandenberghe, A., Pecalvel, C., Hunault, L., Derenne, T., Gillis, C. M., Iannascoli, B., Wang, Y., Rose, T., Mertens, C., Nicaise-Roland, P., …, & Bruhns, P. (2024). Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.ado4463
Vancouver
Dejoux A, Zhu Q, Ganneau C, Goff OR, Godon O, Lemaitre J, et al. Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models. Science Translational Medicine. 2024. doi:10.1126/scitranslmed.ado4463
BibTeX
@article{Dejoux2024,
author = {Dejoux, Alice and Zhu, Qianqian and Ganneau, Christelle and Goff, Odile Richard-Le and Godon, Ophélie and Lemaitre, Julien and Relouzat, Francis and Huetz, François and Sokal, Aurélien and Vandenberghe, Alexis and Pecalvel, Cyprien and Hunault, Lise and Derenne, Thomas and Gillis, Caitlin M and Iannascoli, Bruno and Wang, Yidan and Rose, Thierry and Mertens, Christel and Nicaise-Roland, Pascale and NASA Study Group, NASA Study Group and England, Patrick and Mahévas, Matthieu and de Chaisemartin, Luc and Le Grand, Roger and Letscher, Hélène and Saul, Frederick and Pissis, Cédric and Haouz, Ahmed and Reber, Laurent L and Chappert, Pascal and Jönsson, Friederike and Ebo, Didier G and Millot, Gaël A and Bay, Sylvie and Chollet-Martin, Sylvie and Gouel-Chéron, Aurélie and Bruhns, Pierre},
title = {Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models},
journal = {Science Translational Medicine},
year = {2024},
doi = {10.1126/scitranslmed.ado4463}
}
EUVIMED